Session: 184. Late Breaker Oral Abstract Session 2 Friday, October 4, 2019: 1:55 PM Background. Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) has been implicated in greater weight gain than other regimens among people with HIV, but there is little evidence about its role in serious clinical outcomes proximal to weight gain. We therefore examined the impact of initial ART regimen class/drug on incident diabetes mellitus (DM) in a large North American HIV cohort.
Background. The development of a safe and effective vaccine to prevent chronic hepatitis C virus (HCV) infection is a critical component of elimination efforts, providing the rationale for the first HCV vaccine efficacy trial.
Methods. In a randomized, multicenter, double-blind, placebo-controlled efficacy trial (NCT01436357), we evaluated a recombinant chimpanzee adenovirus 3 vector vaccine prime followed by a recombinant modified vaccinia Ankara boost, both encoding nonstructural proteins of HCV. HCV-uninfected adults 18-45 years old at-risk for HCV infection due to injection drug use were randomized to receive the prime-boost regimen or placebo at Days 0 and 56. Trial participants were monitored for vaccine reactogenicity, adverse events, and HCV viremia. Vaccine safety, immunogenicity, and efficacy against progression to chronic HCV infection were assessed.
Results.
A total of 455 subjects received the prime-boost regimen or two doses of placebo, with 202 and 199 in the respective groups included in the according-to-protocol efficacy cohort. Overall incidence of infection was 14.1 infections per 100 person-years. There were no differences in development of chronic infection between vaccine and placebo arms, with 14 chronically infected subjects in each group. Specifically, the vaccine efficacy in preventing chronic infection was −0.53 (95% confidence interval [CI], −2.5 to 0.34). Of vaccinated subjects, 78% generated T-cell responses to ≥1 vaccine-encoded HCV antigens. The vaccine was generally safe and well tolerated with no serious vaccine-related adverse events. There were more solicited reports of adverse events after either injection in the vaccine group (81%) than in the placebo group (59%), with the difference mainly due to injection-site reactions. Serious adverse events and deaths occurred with similar frequencies in the two groups.
Conclusion. A randomized, placebo controlled, Phase I/II trial of a prime-boost vaccine to prevent chronic HCV infection was completed in an at-risk population, demonstrating the feasibility of conducting rigorous vaccine research in people who inject drugs. The regimen elicited robust immune responses without evident safety concerns, but did not provide protection against chronic HCV infection.
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LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
Jane Maclennan, BSc MRPharmS 1 ; Heinz Weidenthaler, MD 1 ; Phillip Pittman, MD 2 ; Darja Schmidt, PhD 1 ; Paul Chaplin, PhD 1 ; 1 Bavarian Nordic, Martinsried, Bayern, Germany,; 2 USAMRIID, Fort Detrick, Maryland Session: 184. Late Breaker Oral Abstract Session 2 Friday, October 4, 2019: 2:15 PM Background. Smallpox remains a high-priority threat due to its potential for re-emergence through events including bioterrorism and spontaneous mutation. While traditional replicating smallpox vaccines such as ACAM2000 are associated with serious side effects, the non-replicating MVA BN smallpox vaccine was developed as a safer alternative.
Methods. This phase 3 non-inferiority study compared indicators of efficacy between the MVA-BN smallpox vaccine and ACAM2000. The co-primary endpoints were (1) to compare vaccine-induced serum neutralizing antibodies (geometric mean titer [GMT]) at predefined Peak Visits, as measured by plaque reduction neutralization tests (PRNT) and (2) to assess the attenuation of ACAM2000-induced takes after MVA-BN administration by measuring maximum lesion area (MLA). Early neutralizing antibody GMTs at Day 14, a timepoint considered protective for traditional replicating smallpox vaccines, were also compared following single doses of either vaccine.
Results. A total of 440 subjects were evenly randomized to receive either 2 doses of MVA-BN followed by 1 dose of ACAM2000 at 4 week intervals (Group 1) or a single dose of ACAM2000 (Group 2). Peak neutralizing antibody GMTs were significantly higher following 2 MVA-BN doses (153.5) compared with ACAM2000 (79.3), with a ratio of 1.935 (95% CI: 1.562, 2.397). At Day 14, neutralizing antibody GMTs were equal following a single dose of either MVA BN or ACAM2000 (16.2, ratio of 0.997, 95% CI: 0.738, 1.348), with similar seroconversion rates (90.8% vs. 91.8%, respectively). The median MLA induced by ACAM2000 was significantly reduced when subjects received prior MVA-BN in Group 1 (0 mm 2 ) compared with Group 2 (76.0 mm 2 ), suggesting protection against orthopoxvirus. MVA BN was well tolerated, demonstrating a better safety profile than ACAM2000.
Conclusion. Two doses of MVA-BN induce significantly higher peak neutralizing antibody responses compared with ACAM2000. A single dose induces an early neutralizing antibody response equal to ACAM2000 at Day 14, demonstrating the suitability of MVA BN in both pre-and post-outbreak scenarios. This study was partly funded by BARDA under contract HHSO100200700034C.
Disclosures. Jane Maclennan, BSc MRPharmS, Bavarian Nordic (Employee), Bavarian Nordic (Employee, Shareholder), Heinz Weidenthaler, MD, Bavarian Nordic (Employee, Shareholder), Phillip Pittman, MD, Bavarian Nordic (Scientific Research Study Investigator), Darja Schmidt, PhD, Bavarian Nordic (Employee, Shareholder), Paul Chaplin, PhD, Bavarian Nordic (Board Member, Employee, Shareholder), Bavarian Nordic (Employee, Shareholder). Background. While vaccine effectiveness varies across seasons and age groups, influenza vaccination is still the most effective means of preventing influenza infection. Current vaccine effectiveness improvement efforts are focused on manufacturing methods whereby the use of eggs as a growth medium is being minimized to prevent egg adaptation mutations that render the vaccine less effective. This study compared children's immune response to two FDA-approved influenza vaccines, cell-based vs. egg-based, in an unblinded randomized controlled trial.
LB12. A Randomized

Methods.
Racially diverse, healthy children ages 4-20 years were randomly assigned 1:1 in blocks of 4 to receiveeither quadrivalent inactivated cell-based or eggbased influenza vaccine. Blood was drawn at Day 0 before vaccination and at Day 28 post vaccination (range = 19-35 days) and analyzed for hemagglutination inhibition (HAI) titers using standard protocols against egg-grown vaccine antigens. Primary outcome measures were seropositivity, defined as HAI titer ≥1:110 and ≥1:40; seroconversion, defined as the HAI titer ratio of Day 28/Day 0 ≥4 and HAI titer at Day 28 ≥40; and fold-rise, defined as antilog of average log 2 HAI titer ratio of Day 28/Day 0. Secondary outcomes were compared for those vaccinated and not vaccinated the previous year.
Results. Baseline demographics including age, sex, race, ethnicity, parental educational status, health insurance coverage, and exposure to household smoking did not differ between vaccine groups. There were no differences in any HAI antibody response between the two vaccine groups (table). Participants unvaccinated in the prior season (2017-2018, N = 62) were more likely than those vaccinated (N = 86) to seroconvert to any strain in 2018-2019 (≥1 strain seroconverted: 68% unvaccinated vs. 35% vaccinated in 2017-2018, P < 0.001). Day 28 titer fold-rise difference was 2.0 for A/H1N1, 0.65 for A/H3N2, 1.1 for B/Colorado and 0.9 for B/Phuket.
Conclusion. There were no differences for any HAI antibody titer outcome between children receiving the two vaccines. Overall, the cohort had HAI titers at levels sufficient to be considered seropositive at baseline. Those unvaccinated in the preceding season had higher seroconversion rates than those vaccinated in both seasons. Bebi Yassin-Rajkumar, n/a 8 ; Dave Anderson, PhD 9 ; Vlad Popovic, MD 9 ; Francisco Diaz-Mitoma, MD 9 ; 1 Vaccine Research Center, Tampere, Pirkanmaa, Finland,; 2 Dalhousie University, Halifax, Nova Scotia, Canada,; 3 University of Antwerp, Campus Drie Eiken, Wilrijk, Antwerpen, Belgium,; 4 Ghent University and Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium,; 5 Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium,; 6 VBI Vaccines Inc., Ottawa, Ontario, Canada,; 7 SciVac Ltd., Rehovot, HaMerkaz, Israel,; 8 Sponsor, Ottawa, Ontario, Canada,; 9 VBI Vaccines, Cambridge, Massachusetts Session: 184. Late Breaker Oral Abstract Session 2 Friday, October 4, 2019: 2:35 PM Background. Many adults fail to achieve seroprotection after receiving 3 doses of monovalent HepB vaccines such as Engerix-B® and the response decreases with age and with common co-morbidities. Sci-B-Vac™ is a trivalent HepB vaccine produced in mammalian cells, adjuvanted with aluminum hydroxide, which in addition to small S antigen, contains preS1 and preS2 antigens expressing highly immunogenic T-and B-cell epitopes that may enhance seroprotection rates (SPR) in adults.
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Methods. In a multicentre study, the immunogenicity of 10 µg dose of Sci-B-Vac™ was compared with a 20-µg dose of Engerix-B® given at days 0, 28, and 168 (NCT03393754). Randomization was stratified by study center and age (18-44, 45-64, ≥65 years) . Immunogenicity, including SPR (% subjects with anti-HBs levels ≥10 mIU/ mL), and safety outcomes were followed to Day 336. The co-primary objectives were (1) non-inferiority in adults ≥18 years and (2) 45-64 (14.7% [9.8-19 .8%]) and ≥ 65 (18.9% [11.6-26.1%]) years. No major safety signals were observed; solicited and unsolicited adverse events were consistent with the known vaccine safety profiles.
Conclusion.
Sci-B-Vac™ met immunogenicity endpoints for non-inferiority in adults aged ≥ 8 years and was superior in adults aged ≥45 years, compared with the monovalent vaccine, Engerix-B®. Sci-B-Vac™ SPR was higher compared with Engerix-B® in key subgroups. No safety signals were observed and safety and tolerability were consistent with the known profile of Sci-B-Vac™. 
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